NCT07457528 2026-03-11
Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
Clinical Trials
36 trialsNCT04821778 2026-01-21
Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3 Recruiting
NCT04821843 2026-01-21
Neoadjuvant Treatment Modalities in Esophageal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3 Recruiting
NCT07312578 2025-12-31
Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma
Peking University
Phase 2 Enrolling by invitation
NCT07277452 2025-12-11
NOTABLE-309
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Not yet recruiting
NCT06770452 2025-09-23
HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients
Zhejiang University
Phase 2 Recruiting
NCT06048913 2025-07-04
Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Completed
NCT06988956 2025-05-25
Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT06938503 2025-04-22
AG Plus Nimotuzumab Sequential Irreversible Electroporation Ablation for Locally Advanced Pancreatic Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT05278728 2025-02-07
Phase IIa Study of Nimotuzumab to Treat Colorectal Cancer
Biotech Pharmaceutical Co., Ltd.
Phase 1/2 Completed
NCT06722911 2024-12-09
Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer
Zhejiang Provincial People's Hospital
Phase 2 Recruiting
NCT06389760 2024-10-31
Nimotuzumab Combined With mFOLFIRINOX/GX as Postoperative Adjuvant Therapy in Pancreatic Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Recruiting
NCT06429839 2024-05-28
Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT06422156 2024-05-20
Nim-PC-28
Peking University Third Hospital
Phase 2 Not yet recruiting
NCT04207918 2024-05-16
A Phase II Study of Chemoradiotherapy With Nimotuzumab in Unresectable Esophageal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Completed
NCT06410651 2024-05-13
Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT06409429 2024-05-10
Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2/3 Not yet recruiting
NCT06404840 2024-05-08
Evaluating Nimotuzumab in Combination With AG Regimen for Pancreatic Cancer With Liver Metastases : A Prospective, Single-Arm, Phase II Study
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT06405685 2024-05-08
Nimotuzumab Plus AG in Pancreatic Cancer With Liver Metastasis
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT06363084 2024-04-12
A Retrospective Study for Nimotuzumab Plus Postoperative Adjuvant Chemotherapy for Resectable Pancreatic Cancer
Ruijin Hospital
Completed
NCT02395016 2024-04-04
A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic Cancer
Biotech Pharmaceutical Co., Ltd.
Phase 3 Completed
NCT06343116 2024-04-02
NOTABLE-308
Biotech Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT02591784 2022-03-17
Nimotuzumab in Combination With Radiotherapy for Esophageal Cancer
Biotech Pharmaceutical Co., Ltd.
Phase 2 Completed
NCT03766178 2021-07-07
Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital of Zhengzhou University
Phase 2 Unknown
NCT02272699 2021-03-18
Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable Esophageal Squamous Cell Carcinoma
Peking University
Phase 2/3 Withdrawn
NCT03400592 2018-01-17
NIEGA
Peking University
Phase 2 Unknown
NCT02945267 2016-10-26
Nimotuzumab Plus S1 Versus Placebo Plus S1 as Maintenance Treatment in Patients With Unresectable Pancreatic Cancer
Chinese PLA General Hospital
Phase 4 Unknown
NCT00950417 2015-08-19
Nimotuzumab in Combination With Chemoradiation for Esophageal Cancer
Biotech Pharmaceutical Co., Ltd.
Phase 1 Completed
NCT02034968 2015-03-05
Nimotuzumab Plus Nab-paclitaxel and Cisplatin in Treating Patients With Advanced Esophageal Carcinoma
Zhejiang University
Phase 2 Withdrawn
NCT02041819 2015-03-05
Neoadjuvant Chemotherapy of Nimotuzumab Plus Nab-Paclitaxel in Squamous Cell Carcinoma of Esophagus
Zhejiang University
Phase 2 Withdrawn
NCT02011594 2015-02-12
Phase II Study of Maintenance Treatment of Nimotuzumab for Advanced Esophageal Carcinoma
Zhejiang University
Phase 2 Withdrawn
NCT01993784 2013-11-25
Study of Nimotuzumab to Treat Esophageal Squamous Cell Carcinoma.
Peking University
Phase 1/2 Unknown
NCT01382745 2013-01-28
Nimotuzumab With Radiotherapy in the Treatment of Anal Canal Cancers
Sir Mortimer B. Davis - Jewish General Hospital
Phase 2 Terminated
NCT01402180 2011-07-26
Nimotuzumab
Fudan University
Phase 2/3 Unknown
NCT01336049 2011-04-15
Nimotuzumab Plus Paclitaxel and Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer
Peking University
Phase 2 Unknown
NCT00972465 2009-09-07
Study of Nimotuzumab to Treat Colorectal Cancer
Peking University
Phase 2 Unknown